LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorThe First Affiliated Hospital of Guangzhou Medical University
About this trial
This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.
Eligibility criteria
Qualifiers
Signing of the informed consent form;
Male or female, aged 18-75 years;
Patients with lung nodules confirmed by CT examination;
Good preoperative pulmonary function cooperation and complete reporting;
Disqualifiers
Poor preoperative pulmonary function cooperation or missing reports;
Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
Trial design
Treatments tested in this trial
- Using tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov